巴曲酶对脑梗死患者血浆内皮素及降钙素基因相关肽水平的影响

目的探讨巴曲酶对急性脑梗死患者血浆内皮素（ET）、降钙素基因相关肽（CGRP）水平的影响。方法60例急性脑梗死患者按数字表法随机分为治疗组和对照组各30例，对照组给予曲克芦丁，1．0g／d，加入5％葡萄糖注射液中静脉滴注，噻氯匹定，0．25g／d，口服；治疗组在对照组治疗的基础上联合应用巴曲酶注射液，剂量为第1、3、5天分别为10u、5u、5u，加入5％葡萄糖注射液中静脉滴注，7d为一疗程。采用放射免疫法检测两组患者治疗前后血浆ET及CGRP水平变化。结果治疗组治疗后血浆ET、CGRP水平分别为（81．25±27．38）、（44．13±13．30）ng／L，与治疗前的（109．83±38．24）、（24．73±13．59）ng／L相比较，差异均有统计学意义（均P〈0．01），与对照组治疗后的（98．07±30．39）、（37．02±12．41）ng／L比较，差异均有统计学意义（均P〈0．01）。结论巴曲酶能调节ET／CGRP之间的平衡，保护脑细胞与血管内皮细胞。

Effect of batroxobin on endothelin and calcitonin gene-related peptide in patients with acute cerebral infarction

Objective To investigate the effect of batroxobin on the plasma levels of endothelin (ET) and calcitonin gene-related peptide(CGRP) in patients with acute cerebral infarction(ACI). Methods 60 patients with ACI were randomly divided into therapy group(n = 30) and control group(n = 30),500 ml of 5% GS plus 1.0g ramme of Troxerutin was intravenously dripped par day and ticlopidine 250mg/day in the control group. Based on the control group therapy,Batroxobin was intravenously dripped with 10U on the 1st day and 5U on the 3rd and 5th day for seven days. The plasma levels of ET and CGRP were detected pre and post treatment by radioimmunoassay. Results Plasma levels of ET and CGRP in batroxobin therapy group post treatment ( 81.25±27.38 ) ; ( 44. 13±13.30) ng/L were significantly different from those pre treatment(109. 83±38.24) ; (24. 73±13.59) ng/L (all P＜0. 01 ) ,and were also significantly different from those post treatment in the control group(98.07±30. 39) ; (37.02±12. 41 )ng/L (all P＜0. 01 ). Conclusion Batroxobin can accommodate the equilibration between ET and CGRP, and protect brain cell and blood vessel endothelial cell.